U.S. Department of Health and Human Services

The U.S. Department of Health and Human Services is presented as a federal authority shaping access to medication-assisted treatment (MAT) during the opioid crisis. Its rules limited the number of patients that certified clinicians could treat, while later federal funding and public statements by its leadership reflected competing views about the role of medication in recovery. The account places these national decisions beside the costs, waiting lists, and local workarounds faced by patients and families seeking care.

Federal limits and access to treatment

At the time described, federal Health and Human Services rules capped MAT-certified doctors at 100 patients. The limit was raised to 275 later that year in response to the opioid crisis, but a change in the ceiling did not immediately resolve the shortage of treatment. In Virginia, people still encountered limited provider capacity, wait lists, and substantial out-of-pocket costs. Tess Henry’s buprenorphine medication was mostly covered by insurance, but her addiction-doctor visits required cash payments: $700 up front and $90 to $100 for each follow-up, with as many as four visits in a month. Her mother, Patricia, also described cash-only practices and long waits as obstacles to care.

The treatment pathway could be fragile before patients even reached ongoing care. After an earlier ten-week rehabilitation program in Jacksonville, Jesse Bolstridge had briefly received buprenorphine, then was tapered off after three weeks; his mother, Kristi Fernandez, still owed $25,000 for the program. The book contrasts such short-term approaches with evidence favoring longer-term medication alongside behavioral treatment and recovery support. These cases clarify the practical stakes of rules that determine how many patients clinicians can serve: formal permission to prescribe does not guarantee an affordable appointment, continuity of medication, or a supported transition between treatment settings.

Funding and disagreement over MAT

In the spring after 2016, Health and Human Services Secretary Tom Price released the first half of the $1 billion Congress had appropriated under the 21st Century Cures Act for treatment and prevention, including expanded access to MAT. A month later, Price publicly characterized MAT as replacing one opioid with another, disappointing treatment advocates. The account reports that Nora Volkow, director of the National Institute on Drug Abuse, presented him with scientific evidence supporting MAT; Price resigned a few months afterward amid a scandal involving taxpayer-funded charter flights. In February 2018, his successor, Alex M. Azar II, indicated that the administration would significantly expand access to MAT.

This sequence places federal spending beside a continuing dispute about what counts as treatment. The book describes resistance to MAT not only in public policy but also in treatment settings, including recovery groups and Virginia drug courts that prohibited its use. HHS leadership therefore appears within a broader conflict: federal funds could support expanded access, while the public framing of medication by senior officials could either reinforce or weaken confidence in that approach.

National policy and local care

The distance between federal policy and treatment on the ground remains central to the account. In Virginia, Dr. Hughes Melton worked with state Medicaid officials to broaden reimbursement and include payment for required counseling and care coordination, partly to encourage cash-only clinics to accept insurance, including Medicaid. The Governor’s Access Plan offered additional treatment and services to 14,000 Virginians, but reached only a fraction of those in need and did not do so until 2017. These state and local measures were distinct from HHS rules, yet they show the implementation problem surrounding federal limits and funding: service capacity, payment arrangements, and administrative access all shaped whether treatment could be reached.

Roanoke’s Hope Initiative illustrates another local response. Its volunteers assembled a five-page spreadsheet listing 36 rehabilitation and aftercare providers across the southeastern United States, matching possible referrals to patients’ finances and available beds. At the Bradley Free Clinic, people without outstanding warrants could meet trained volunteers who helped troubleshoot care, while social-service workers assisted eligible applicants with Medicaid. The effort made navigation itself part of treatment, but the account also notes disagreement among volunteers about MAT, including opposition to treating addiction with another medication.

Treatment continuity and the limits of reform

Later efforts sought to make the transition from emergency care to continuing treatment more direct. Warren Bickel received a $1 million grant for a Virginia Tech Carilion Research Institute pilot testing protocols to connect overdose patients from emergency rooms to outpatient buprenorphine, including through a once-monthly injection. The project responded to a system in which an overdose encounter did not necessarily lead to sustained care. In Roanoke, the community services board had added MAT for 21 patients, conditional on their first engaging in counseling, while Carilion still had a three-week wait for outpatient MAT.

Together, the patient cap, the later increase, federal treatment funding, and the local service examples show both the reach and limits of HHS’s role in the book. Federal policy could set prescribing capacity and allocate resources, but access depended on clinicians, insurance and Medicaid reimbursement, available beds, appointment waits, and continuity after an emergency. The account treats those links as consequential: expanding a rule or announcing funding mattered, but patients still had to get through each step between seeking help and remaining in care.